Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | WHR1 | P49842 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24183091 | 0.95 | MEN1 (0.44) | MEN1KMT2AATMWHR1PDK1 | |
| SCHEMBL22017776 | 0.94 | KMT2A (0.44) | MEN1KMT2AATMWHR1PDK1 | |
| SCHEMBL22015147 | 0.94 | MEN1 (0.34) | MEN1KMT2AATMWHR1GAA | |
| SCHEMBL24182822 | 0.94 | MEN1 (0.34) | MEN1KMT2AATMWHR1GAA | |
| SCHEMBL24182986 | 0.94 | MEN1 (0.41) | MEN1KMT2AATMWHR1PDK1 | |
| SCHEMBL24182959 | 0.94 | MEN1 (0.41) | MEN1KMT2AATMWHR1PDK1 | |
| SCHEMBL22015130 | 0.92 | WHR1 (0.35) | MEN1KMT2AATMWHR1GAA | |
| SCHEMBL22015133 | 0.91 | WHR1 (0.33) | MEN1KMT2AATMWHR1 | |
| SCHEMBL24182814 | 0.91 | MEN1 (0.33) | MEN1KMT2AATMWHR1MAPT | |
| SCHEMBL22015134 | 0.91 | MEN1 (0.33) | MEN1KMT2AATMWHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220013729-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2022-01-13 | — | — | US | disclosed |
| WO-2020101314-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME | 엘티소재주식회사 | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220013729-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME | CRY1, CYP1B1, CYP1A1 | MEN1 700/4885KMT2A 656/4885ATM 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.